Extended Data Fig. 7: Somatic mutations and copy number variations (CNVs) in three subtypes. | Nature Cancer

Extended Data Fig. 7: Somatic mutations and copy number variations (CNVs) in three subtypes.

From: Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial

Extended Data Fig. 7: Somatic mutations and copy number variations (CNVs) in three subtypes.

a, Oncoprints for somatic mutations and CNVs in subtype 1 (S1, n = 18), S2 (n = 13) and S3 (n = 15) tumors. Horizontal bars to the right indicate the number of samples with an alteration and the types of alterations in indicated gene. Bar plots at the top show the total number of genetic alterations in the oncoprint genes. Horizontal bars and bar plots are colored by the alteration type. b, Percentage of subtypes (S1, n = 18; S2, n = 13; and S3, n = 15) tumors in patients with mutation in 13 selected genes. c, Pathways (based on the MSigDB v6.2 Hallmarks gene sets) with significant difference in patients (n = 46) with vs without mutation in 13 selected genes. Red (vs blue) discs represent for enriched (vs repressed) gene sets with disc areas for the areas-under-the-curve (AUCs) by the CERNO test.

Source data

Back to article page